In an emulated target trial, a single dose of modified vaccinia Ankara-Bavarian Nordic vaccine was moderately effective in ...

MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMARepresents ...

One dose of modified vaccinia Ankara-Bavarian Nordic vaccine is moderately effective against mpox infection in at-risk communities.

Mpox vaccines have been administered in Africa for the first time, with several hundred high-risk individuals vaccinated in ...

The rate of mpox infection in the vaccinated group was 0.09 for every 1,000 person-days as compared to 0.20 in the ...

Gavi (the Global Alliance for Vaccines and Immunization) has entered an advance purchase agreement with Bavarian Nordic to secure 500,000 doses of the modified vaccinia Ankara-Bavarian Nordic (MVA-BN) ...

Lessons learned from the Covid pandemic have left the world in a much better position to tackle the current mpox epidemic ...

(RTTNews) - Bavarian Nordic A/S (BAVA) Thursday said that the European Commission has adopted the Committee for Medicinal Products for Human Use (CHMP) recommendation for the approval of a type II ...

Lessons learned from the COVID pandemic have left the world in a much better position to tackle the current mpox epidemic ...

The World Health Organization (WHO) has authorized the MVA-BN vaccine as the first vaccine against mpox to be added to its ...

The World Health Organization Friday approved MVA-BN as the first mpox vaccine added to its pre-qualification list.